Q-Line Biotech Limited

<table><tr><td>OXYZO<br>FINANCIAL<br>SERVICES<br>PVT. LTD.</td><td>Business<br>Loan</td><td>Working<br>Capital<br>Requirement</td><td>400.00</td><td>Discount<br>(MCL<br>R-<br>8.80%<br>+Sprea<br>d-<br>5.70%)</td><td>Against<br>Fixed<br>Deposits-<br>200 Lakhs<br>of<br>Innovation</td><td>24.00</td><td>19.30</td><td>05th May 2023 to<br>05th April 2025</td><td>19.19</td><td>-</td><td>-</td></tr><tr><td colspan="11">Total Long Term Borrowing including current Maturities of Long Term Borrowing (A)</td><td>10,837.36</td><td>4,239.15</td><td>1,317.71</td></tr></table>

Short term borrowing

<table><tr><td rowspan="3">Indusland Bank</td><td>Cash<br>Credit/Overdraft</td><td>Cash<br>Credit/Overd<br>raft-<br>Working<br>Capital<br>Requirement<br>**</td><td>675.00</td><td>Inventory & Book<br>Debts, Movable<br>Fixed Assets,<br>Collateral securities<br>as mentioned in<br>point no.4</td><td rowspan="3">Repayable on Demand</td><td rowspan="3">NA</td><td rowspan="3">639.52</td><td rowspan="3">711.89</td><td rowspan="3">321.93</td></tr><tr><td>Overdraft<br>against Fixed<br>Deposits</td><td></td><td>800.00</td><td>Fixed deposits-<br>100% FDOD</td></tr><tr><td>Non Fund<br>Based</td><td>Forward<br>Derivative<br>Contract</td><td>210.00</td><td>As per<br>Bank<br>usual<br>guideli<br>ne</td><td>Not Applicable</td></tr><tr><td rowspan="3">HDFC Bank</td><td>Overdraft/CC</td><td>Working<br>Capital<br>Finance</td><td>2,025.00</td><td rowspan="3">6.25%</td><td rowspan="3">25% on stock,<br>Bood Debts upto<br>120 Days, Cash<br>margin for LC/BG,<br>and As mentioned<br>below-point no.2</td><td rowspan="3">Repayable on Demand</td><td>NA</td><td>1,926.60</td><td>3,404.55</td><td>4,314.17</td></tr><tr><td>Overdraft<br>against Fixed<br>Deposits</td><td>Working<br>Capital<br>Finance</td><td>1,000.00</td><td></td><td></td><td></td></tr><tr><td>Letter of<br>Credit(sub limit<br>of Bank<br>Guarrantee)</td><td>Working<br>Capital<br>Finance</td><td>600.00</td><td></td><td></td><td></td></tr></table>

207